NVO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Novo Nordisk A/S's quarterly accounts payable & accrued expense declined from Jun. 2015 ($1,078 Mil) to Sep. 2015 ($1,077 Mil) but then increased from Sep. 2015 ($1,077 Mil) to Dec. 2015 ($3,001 Mil).
Novo Nordisk A/S's annual accounts payable & accrued expense increased from Dec. 2013 ($2,810 Mil) to Dec. 2014 ($2,984 Mil) and increased from Dec. 2014 ($2,984 Mil) to Dec. 2015 ($3,001 Mil).
Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.
Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.
It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.
* All numbers are in millions except for per share data and ratio. All numbers are in their own currency.
Novo Nordisk A/S Annual Data
|Accounts Payable & Accrued Expense||303||404||428||576||738||789||783||2,810||2,984||3,001|
Novo Nordisk A/S Quarterly Data
|Accounts Payable & Accrued Expense||1,413||2,810||1,111||820||1,065||2,984||1,051||1,078||1,077||3,001|